{% extends "clinical-protocol/master-protocol.j2" %}

{% block title %}
INVESTIGATIONAL NEW DRUG (IND) PROTOCOL
{{ study_name | upper }}
IND Number: {{ ind_number | default("PENDING") }}
Protocol Number: {{ protocol_number }}
{% endblock %}

{% block content %}
{{ super() }}

## DRUG-SPECIFIC SECTIONS

### A. INVESTIGATIONAL DRUG INFORMATION

#### Drug Name
{{ drug_name }} ({{ drug_generic_name | default("generic name pending") }})

#### Drug Classification
{{ drug_classification | default("Pharmacologic class to be determined") }}

#### Formulation
{{ drug_formulation | default("Tablet, capsule, or solution as appropriate") }}

#### Route of Administration
{{ route_of_administration | default("Oral") }}

#### Dosing Regimen
{{ dosing_regimen | default("Dose and frequency to be specified") }}

### B. PHARMACOLOGY

#### Mechanism of Action
{{ drug_mechanism | default("The investigational drug acts by...") }}

#### Pharmacokinetics
{{ pharmacokinetics | default("Absorption, distribution, metabolism, and excretion characteristics...") }}

#### Pharmacodynamics
{{ pharmacodynamics | default("Drug effects and dose-response relationships...") }}

### C. NONCLINICAL STUDIES

#### Toxicology Studies
{{ toxicology_summary | default("Toxicology studies in animals have shown...") }}

#### Genotoxicity
{{ genotoxicity_summary | default("Genotoxicity testing results...") }}

#### Carcinogenicity
{{ carcinogenicity_summary | default("Carcinogenicity studies (if applicable)...") }}

#### Reproductive Toxicology
{{ reproductive_tox_summary | default("Effects on fertility and reproduction...") }}

### D. CLINICAL PHARMACOLOGY

#### Prior Human Experience
{{ prior_human_experience | default("Previous clinical studies have demonstrated...") }}

#### Dose Rationale
{{ dose_rationale | default("The selected dose is based on...") }}

#### Drug-Drug Interactions
{{ drug_interactions | default("Potential interactions with concomitant medications...") }}

### E. DRUG MANUFACTURING

#### Drug Substance
{{ drug_substance_info | default("Active pharmaceutical ingredient information") }}

#### Drug Product
{{ drug_product_info | default("Finished dosage form specifications") }}

#### Stability
{{ stability_data | default("Stability studies support expiration dating of...") }}

#### Supply and Distribution
{{ drug_supply | default("Study drug will be supplied by sponsor") }}

### F. DRUG ADMINISTRATION AND ACCOUNTABILITY

#### Drug Storage
{{ drug_storage | default("Store at 2-8Â°C, protect from light") }}

#### Drug Preparation
{{ drug_preparation | default("No preparation required" if route_of_administration == "Oral" else "Preparation instructions...") }}

#### Drug Accountability
All study drug dispensed and returned will be documented in drug accountability logs.

#### Drug Compliance
{{ compliance_monitoring | default("Compliance will be assessed by pill count and patient diary") }}

### G. CONCOMITANT MEDICATIONS

#### Prohibited Medications
{{ prohibited_meds | default("The following medications are prohibited during the study...") }}

#### Allowed Medications
{{ allowed_meds | default("Stable doses of chronic medications are permitted") }}

#### Rescue Medications
{{ rescue_meds | default("Rescue medications for symptom management...") }}

### H. PHARMACOVIGILANCE

#### Serious Adverse Event Reporting
SAEs will be reported to FDA within 15 calendar days (7 days for fatal/life-threatening).

#### Suspected Unexpected Serious Adverse Reactions (SUSARs)
SUSARs will be reported per FDA IND safety reporting requirements.

#### Pregnancy Reporting
{{ pregnancy_reporting | default("Pregnancies occurring during the study will be followed to outcome") }}

{% endblock %}